Cognitive Behavioral Therapy (CBT) Study Evaluating the Updating of Persecutory Beliefs

Sponsor
Vanderbilt University Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT04748679
Collaborator
(none)
60
1
2
35.1
1.7

Study Details

Study Description

Brief Summary

The purpose of this study is to examine how Bayesian belief updating changes throughout psychotherapeutic treatment for persecutory delusions. Specifically, individuals with a psychotic disorder diagnosis who endorse both a current persecutory delusion with strong conviction and significant worry will be recruited and randomized to receive either a CBT-based worry intervention for persecutory delusions or an active control condition (befriending therapy). The investigators will examine: 1) whether belief updating parameters change as delusion severity changes, 2) whether CBT contributes to greater change in belief updating parameters than befriending therapy, and 3) whether neural correlates of belief updating parameters, as measured using functional magnetic resonance imaging (fMRI), predict treatment response.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Worry Intervention
  • Behavioral: Befriending
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Cognitive Behavioral Therapy (CBT) Study Evaluating the Updating of Persecutory Beliefs
Actual Study Start Date :
Mar 30, 2021
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Mar 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Worry Intervention

The Worry Intervention uses cognitive-behavioral therapy (CBT) techniques to support the patient in reducing the amount of time they worry throughout the week. It is an 8-week manualized treatment with 5 modules. Each session is 45-60 minutes.

Behavioral: Worry Intervention
The worry intervention is weekly individual therapy with a trained therapist

Active Comparator: Befriending

Befriending therapy controls for the general factors of therapy (warmth, engagement) without any 'active' interventions. Individuals in the befriending arm will spend sessions talking with the therapist about things that interest them. It will also be conducted over 8-weeks with 45-60 minute sessions.

Behavioral: Befriending
The worry intervention is weekly individual therapy with a trained therapist

Outcome Measures

Primary Outcome Measures

  1. Computational Parameters of Belief Updating as Measured During a Probabilistic Reversal Learning Task [Baseline, 4 weeks, 8 weeks, 24 weeks]

    change in computational parameters after intervention

  2. Change in Delusion Severity Utilizing the Change in Psychotic Symptoms Rating Scale (PSYRATS) [Baseline, 4 weeks, 8 weeks, 24 weeks]

    The change in the Delusions subscale total of the Psychotic Symptoms Rating Scale (PSYRATS) from Baseline to Week 24. The Delusions subscale is a composite score of 6 items each rated from 0-4 with 4 indicating more severe symptomology. The Delusions subscale has a possible range of 0-24.

  3. Change in Neural Correlates of Belief Updating Parameters [Baseline, 8 weeks]

    Change in blood oxygen dependent level (BOLD) signal after intervention

Secondary Outcome Measures

  1. Baseline Neural Predictors of Treatment Response [Baseline]

    BOLD signal during belief updating task at baseline predicting treatment response

  2. Resting-State Predictors of Treatment Response [Baseline]

    resting-state connectivity of functional networks predicting treatment response

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Men and women age 18 - 65.

  2. Communicative in English.

  3. Premorbid Intelligence >79 (WTAR)

  4. Provide voluntary, written informed consent.

  5. Physically healthy by medical history.

  6. Weight <300 lbs

  7. Stable medication regimen over at least the past two weeks, including the use of either an oral or intramuscular administration of an antipsychotic medication.

  8. Diagnosis of a non-affective psychotic disorder (schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, brief psychotic disorder, psychosis NOS) confirmed by Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)-5 (SCID) or diagnostic interview with a trained clinician.

  9. A persecutory delusion scoring at least a 3 on the conviction scale of the Psychotic Symptoms Rating Scale (PSYRATS) that had persisted for at least two weeks and that was not considered the direct result of substance use

  10. A clinically significant level of worry, as shown by a score of at least 44 on the Penn State Worry Questionnaire (PSWQ).

Exclusion Criteria:
  1. Age less than 18 or greater than 65.

  2. Not communicative in English.

  3. Premorbid IQ < 79 (WTAR)

  4. Unable to provide written informed consent.

  5. Current medical or neurological illness.

  6. History of severe head trauma.

  7. Weight >300 lbs

  8. Primary diagnosis of alcohol or substance use disorder or personality disorder

  9. Conditions that preclude fMRI scanning (as defined in the fMRI Screening Form)

  10. Subjects who are actively involved with individual cognitive therapy (Past experience with individual therapy is not an exclusion)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Vanderbilt University Medical Center Nashville Tennessee United States 37212

Sponsors and Collaborators

  • Vanderbilt University Medical Center

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Julia Sheffield, Assistant Professor of Psychiatry & Behavioral Sciences, Vanderbilt University Medical Center
ClinicalTrials.gov Identifier:
NCT04748679
Other Study ID Numbers:
  • 201882
First Posted:
Feb 10, 2021
Last Update Posted:
Jul 19, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 19, 2022